Transcriptomics

Dataset Information

0

Inhibiting YAP1 in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells


ABSTRACT: Despite advances in surgical care and chemotherapeutic regimens, the five-year survival rate for Stage IV Hepatoblastoma (HB), the predominant pediatric liver tumor, remains at 27%. YAP1 and β-Catenin co-activation occur in 80% of children’s HB; however, a lack of conditional genetic models precludes exploration of tumor maintenance and therapeutic targets. Thus, the clinical need for a targeted therapy remains unmet. Given the predominance of YAP1 and β-catenin activation in children’s tumors, we sought to evaluate YAP1 as a therapeutic target in HB. We engineered the first conditional murine model of HB using hydrodynamic injection to deliver transposon plasmids encoding inducible YAP1S127A, constitutive β-CateninDelN90, and a luciferase reporter to murine liver. Tumor regression was evaluated using in vivo bioluminescent imaging, and tumor landscape characterized using RNA sequencing, ATAC sequencing and DNA foot-printing. Here we show that YAP1 inhibition mediates >90% tumor regression with survival for 230+ days in mice. Mechanistically, YAP1 inhibition induces a cell fate switch driving therapeutic differentiation of HB tumors into Ki-67 negative “hbHep cells” with hepatocyte-like morphology and mature hepatocyte gene expression.

ORGANISM(S): Mus musculus

PROVIDER: GSE146548 | GEO | 2020/07/14

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-03-30 | GSE112485 | GEO
2019-07-18 | GSE133976 | GEO
2017-08-23 | GSE79084 | GEO
2023-11-15 | GSE235202 | GEO
2015-04-30 | E-GEOD-68124 | biostudies-arrayexpress
2019-10-09 | GSE130178 | GEO
2007-08-07 | E-TABM-295 | biostudies-arrayexpress
2017-04-25 | GSE97914 | GEO
2023-03-13 | GSE193980 | GEO
2014-01-23 | E-GEOD-49295 | biostudies-arrayexpress